Dr. Aaron Miller: “Multiple sclerosis patients urge FDA to approve drug”
In November, the Food and Drug Administration rejected a drug for multiple sclerosis that its sister agencies in Europe, Canada, Mexico and Australia had approved. Doctors and patients who want access to the drug Lemtrada have launched a lobbying campaign to get the regulatory agency to change its mind. "Lemtrada appears to be among our most effective, if not the most effective agent in reducing relapses," said Aaron Miller, MD, Professor of Neurology at the Icahn School of Medicine at Mount Sinai, and Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Mount Sinai Health System. Learn more
Two Mount Sinai Experts Receive Honors From the National Multiple Sclerosis Society
Sep 16, 2021 View All Press Releases